https://www.patsnap.com/resources/blog/rd-blog/sterilizing-grade-filtration-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Viral Clearance & Filtration
Sterilizing Grade Filtration Patents: Concentration at the Top, a Cooling Trend
  • 73.3% of all 288 records sit with just five assignees, and the leader alone accounts for 118 records — this is a field with an entrenched core, not an open one.
  • Filings fell 74% from 23 in 2021 to 6 in 2024, the last year the data can treat as complete; 2017 was the peak year at 35.
  • B01D separation processes touch 52.8% of records, but A61K medicinal preparations (26.7%) and A61L sterilising methods (17.4%) show the claims are as much about formulation and process as about membrane hardware.
Get a prior-art report on your approach
288
Published Records
73%
Top-5 Share of All Records
-74%
Filing Growth 2021→2024
US
Leading Jurisdiction

Filing growth compares 2021 (23 records) with 2024 (6) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 288 records in scope (CR5), not by the ranked leaders only.

Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview

What this patent landscape covers

Sterilizing grade filtration sits at the intersection of membrane science, aseptic process validation and drug manufacturing compliance. The dataset behind this page covers 288 published records filed between 2015 and mid-2026, drawn from claims touching bubble point testing, bacterial retention, filter validation, adsorptive product loss, flow decay and extractable profiles — the technical vocabulary regulators and manufacturers actually use when qualifying a sterilizing filter for pharmaceutical use.

The picture that emerges is one of a mature, consolidated field. A small number of assignees built dense patent estates around core filter validation and membrane construction techniques years ago, and the pace of new filing has slowed sharply since. That does not mean the technology is settled — publication lags filing by roughly 18 months, so the most recent years understate real activity — but it does mean anyone entering now is filing into occupied territory rather than open ground.

Filing activity and technology composition, 2015–2026
  1. 1EMD MILLIPORE CORP118
  2. 2TEVA PHARMA IND LTD53
  3. 3NXSTAGE MEDICAL INC19
  4. 4ENTEGRIS INC11
  5. 5MERCK MILLIPORE LTD10
  6. 6BAXTER HEALTHCARE SA9
  7. 7BAXTER INT INC9
  8. 8TKACIK GABRIEL7
  9. 9PUROPORE6
  10. 10W L GORE & ASSOC GMBH6
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Sterilizing Grade Filtration covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Numbers

Filing trends and technology composition

Two views of the same 288 records: how filing activity has moved year over year, and which IPC subclasses the claims actually fall under.

Filing trend: a sharp pullback from the 2017 peak

Filings peaked at 35 in 2017 and have declined since; the -74% move from 23 filings in 2021 to 6 in 2024 marks the last year the trend can be read as complete, since 2025 and 2026 are still filling in under normal publication lag.

Filing trend: a sharp pullback from the 2017 peak0102030403520172018201920202021202220232024202532026Most recent year is partial — publication lag means later filings are not yet visible.

Technology composition: filtration hardware dominates, but not alone

B01D (separation processes) appears in 52.8% of the 288 records, confirming membrane and housing claims as the technical core. A61K (26.7%) and A61L (17.4%) show a large share of filings are anchored in the drug formulation or the sterilizing method rather than the filter itself, and G01N (14.2%) reflects how much of the field is validation and testing methodology, not the physical filter.

Technology composition: filtration hardware dominates, but not aloneB01D · Separation processes (filtrati…15252.8%A61K · Medicinal preparations7726.7%A61L · Sterilising & disinfecting5017.4%G01N · Material analysis & testing4114.2%A61P · Therapeutic activity of compou…3612.5%A61M · Devices for body fluids3010.4%C02F · Water & wastewater treatment155.2%A61J · Containers for medicine134.5%Other10737.2%

Shares are the percentage of the 288 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.

Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Sterilizing Grade Filtration covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.

Go deeper on Sterilizing Grade Filtration with Eureka

This page is one run against one query. Ask Eureka your own question about sterilizing grade filtration and every answer comes back with the patent numbers behind it.

Try Eureka
Key Patents

Representative and most-cited filings

Representative Recent Filing
US20260200613A12026-07-16

Method for preparing a filling operation

GRONINGER & CO. GMBH

A method for preparing a filling operation that wets each filter element with a defined amount of pharmaceutical liquid before passing the liquid through a filter assembly arranged between a liquid source and a filling device inside a barrier-controlled filling system.Filed by Groninger & Co. GmbH, published 2026-07-16 — illustrative of how recent filings frame sterilizing filtration as part of an integrated aseptic filling process rather than a standalone membrane claim.

US20260200613A1 — patent drawing 1US20260200613A1 — patent drawing 2
View full filing
Most-cited records in scope
#Publication no.Patent titleCitations
1WO2010107503A1Removal of microorganisms from fluid samples using nanofiber filtration media71
2US5064529AApparatus for testing membrane filters71
3US20070089489A1Methods and systems for integrity testing of porous materials66
4US4872974AApparatus for testing membrane filters, and for sterilizing liquids with use of membrane filter66
5US20130092622A1Nanofiber containing composite membrane structures65
6US7594425B2Methods and systems for integrity testing of porous materials57
7US20120091072A1Removal of microorganisms from fluid samples using nanofiber filtration media50
8EP0139202A1Apparatus for testing membrane filters, and apparatus for sterilizing liquids with use of membrane filter47
9US20140116945A1Nanofiber containing composite structures45
10EP1775015A1A method of assessing the integrity of a porous material36

Citation counts favour older filings in any searched corpus — read these as markers of influence on later filers, not as a measure of current commercial importance.

Each row carries its publication number; clicking a row searches Eureka by that number.

Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Sterilizing Grade Filtration covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself

Put your own technology through the same analysis


  
Where to run it
Fastest

Eureka on the web

When you want the answer in the next five minutes.

The agent works the prompt against patents and technical literature, citing every source.

Run your analysis now →
For builders

MCP server & REST API

When it has to run inside your own pipeline.

Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.

Browse MCP servers →
Insights

What the data tells a filing strategy

Three signals stand out once the ranking, trend and technology composition are read together.

Concentration
73.3% of 288 records
held by the top 5 assignees

The core claim space is already occupied

With the leading assignee alone holding 118 records and the top five combined controlling 73.3% of all 288 records in scope, foundational bubble point testing and membrane integrity claims are heavily staked. New entrants competing head-on in filter housing or basic integrity-test design face dense prior art from a handful of established filers.

Concentration figures per assignee ranking
Momentum
-74% (2021→2024)
filing decline, last complete years

Filing activity has cooled from its 2017 peak

Filings dropped from 23 in 2021 to 6 in 2024, continuing a decline from the 2017 peak of 35. Several of the largest historical filers show zero filings in the latest tracked year, consistent with a field where the founding wave of patents has already been laid down rather than one still being actively built out.

Trend uses 2024 as last complete year; 2025-2026 still filling in
Composition
26.7% carry A61K
medicinal preparation claims

Claims blend hardware with formulation and process

More than a quarter of the 288 records carry A61K medicinal preparation classes and 17.4% carry A61L sterilising method classes alongside the filtration classification, meaning many patents protect a formulation-plus-filter or process-plus-filter combination rather than a filter component in isolation.

IPC shares sum above 100% since records carry multiple classes
Eureka AI Agent
Looking for what nobody has claimed yet?

Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to sterilizing grade filtration, with the prior art for and against each one.

Find the white space →
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Sterilizing Grade Filtration covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Who's Filing

The assignee landscape

The ranked list covers 39 companies across the 288 records in scope — not a top-50 or top-100 cut, but the entire ranking the dataset returns.

Leader
118 records
single largest assignee

One filer dominates the ranking

The leading assignee's 118 records are more than double the combined total of the next four ranked entrants, reflecting decades of accumulated filtration and validation patent activity concentrated in one estate.

Leader vs. fifth place: 118 vs. 10
Mid-field
10 records
fifth-place assignee

A steep drop after the leader

Filing volume falls off quickly outside the top handful of names: fifth place holds 10 records and tenth place holds 6, meaning the field narrows fast from one dominant filer to a long tail of much smaller portfolios.

Top 10 combined: 248 records, 86.1% of all 288
Collaboration
10 co-assignee pairs
identified in the dataset

Co-filing is limited and concentrated

Only 10 co-assignee pairs appear across the dataset, and the strongest pairing repeats across multiple records, suggesting joint filing here tends to happen within long-running individual or corporate partnerships rather than broad industry consortia.

Strongest pair recurs across 9 shared records
🔍
Under-claimed sub-areas worth checking before filing
Branches with comparatively thin coverage relative to the core filtration and validation claims
Extractable/leachable profiling methodsRedundant filtration train designFlow decay predictive modellingWater and wastewater sterilizing filtration (C02F, 5.2%)Single-use filter assembly containers (A61J, 4.5%)
Rank all filers by momentum →
Recent-year filing momentum
AssigneeRecent yearYoY
EMD Millipore Corp0-100%
Teva Pharmaceutical Industries Ltd0—
NxStage Medical Inc0—
Entegris Inc0—
TKACIK GABRIEL0—
Baxter International Inc0—
Baxter Healthcare SA0—
KOZLOV MIKHAIL0—
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Sterilizing Grade Filtration covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next

Where to take this analysis

The dataset points to a consolidated field with narrow but real gaps. These are the natural next steps for a team deciding whether and where to file.

Map claims against the leading estate

Before drafting in bubble point testing or bacterial retention, check how the leading assignee's 118 records actually cover the specific test parameters or membrane construction you plan to claim.

Explore assignee portfolios in Eureka

Test white space in adjacent classes

C02F and A61J carry the thinnest coverage among the tracked IPC subclasses; a first claim there would need to show clear technical distinction from the dominant B01D filtration hardware art.

Run a white space search in Eureka

Watch for renewed filing activity

Filing has cooled since 2017, but 2025-2026 figures are still incomplete under normal publication lag; monitor whether momentum resumes before concluding the field has settled.

Set up filing alerts in Eureka
Source: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Sterilizing Grade Filtration covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ

Common questions about sterilizing grade filtration patents

Answers are grounded in the same dataset. Derived from a Patsnap search on Sterilizing Grade Filtration covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Research Sterilizing Grade Filtration in depth with Eureka

Go past this page: query the whole sterilizing grade filtration corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.

Try Eureka

Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.

Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.

Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.

Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.

Help us improve

Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.